SLC5A2 and xerostomia: Although SGLT2 inhibitors are primarily designed for glycemic control in diabetes management and, more recently, for its cardiac and renal protection, they have been associated with various oral adverse effects, for example, xerostomia, which can contribute to or worsen BMS symptoms [7].